Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Cytek BioSciences Inc (NASDAQ: CTKB) was $5.31 for the day, up 1.53% from the previous closing price of $5.23. In other words, the price has increased by $1.53 from its previous closing price. On the day, 0.65 million shares were traded.
Ratios:
Our analysis of CTKB’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.78. For the most recent quarter (mrq), Quick Ratio is recorded 5.47 and its Current Ratio is at 6.21. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on January 31, 2025, Downgraded its rating to Sell and sets its target price to $4.50 from $7 previously.
On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $9.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 19 ’24 when Yan Ming sold 20,000 shares for $5.87 per share. The transaction valued at 117,400 led to the insider holds 5,988,502 shares of the business.
Yan Ming sold 1,900 shares of CTKB for $13,304 on Apr 09 ’24. The CHIEF TECHNOLOGY OFFICER now owns 6,008,502 shares after completing the transaction at $7.00 per share. On Mar 18 ’24, another insider, Yan Ming, who serves as the CHIEF TECHNOLOGY OFFICER of the company, sold 20,000 shares for $6.77 each. As a result, the insider received 135,400 and left with 6,030,402 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.40 while its Price-to-Book (P/B) ratio in mrq is 1.79.
Stock Price History:
Over the past 52 weeks, CTKB has reached a high of $9.33, while it has fallen to a 52-week low of $4.66. The 50-Day Moving Average of the stock is -12.94%, while the 200-Day Moving Average is calculated to be -9.13%.
Shares Statistics:
A total of 129.77M shares are outstanding, with a floating share count of 116.77M. Insiders hold about 9.35% of the company’s shares, while institutions hold 59.85% stake in the company.
Earnings Estimates
Investors are keenly observing as 3.0 analysts analyze and rate the current performance of Cytek BioSciences Inc (CTKB) in the stock market.The consensus estimate for the next quarter is $0.02, with high estimates of $0.02 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.15 and $0.14 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is $0.15, with 3.0 analysts recommending between $0.17 and $0.14.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $63.5M to a low estimate of $57M. As of the current estimate, Cytek BioSciences Inc’s year-ago sales were $58.6MFor the next quarter, 5 analysts are estimating revenue of $46.12M. There is a high estimate of $48.36M for the next quarter, whereas the lowest estimate is $44.84M.
A total of 6 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $206.4M, while the lowest revenue estimate was $200.11M, resulting in an average revenue estimate of $202.96M. In the same quarter a year ago, actual revenue was $193.39MBased on 5 analysts’ estimates, the company’s revenue will be $216.52M in the next fiscal year. The high estimate is $224.59M and the low estimate is $207.62M.
